United States — United States Agency for International Development & Merck Group

United States — United States Agency for International Development: Its abrupt shutdown disrupted health surveillance funding, hampering the response.

Merck Group: Merck Group's Ervebo vaccine is being deployed in the outbreak response, potentially increasing sales. However, its efficacy against the Bundibugyo strain is unproven, and the trial outcome will be critical.

United States — United States Agency for International Development: USAID's dismantling by the Trump administration directly impaired PEPFAR operations, as it managed many of the grants. The agency's role in global health has been diminished.

Merck Group: Announced plans to allow generic production of alimatravir, potentially expanding market access.

United States — United States Agency for International Development: Agency that was shuttered, affecting health surveillance funding. Its absence has weakened response capacity.

Merck Group: Manufacturer of RVSV-ZEBOV vaccine, which is being considered for cross-protection trials. Its vaccine could play a role in the response, benefiting its reputation.